About the Company
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009. Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers. As of 2024 Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine-based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on SUTRO BIOPHARMA, INC.
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue ... - Nasdaq
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.67 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.33 per share a year ago. These figures are ...
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $6.63 Average Target Price ...
Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) has received a consensus recommendation of “Hold” from the nine brokerages that are currently covering the company, Marketbeat reports.
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Beats Revenue Estimates
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.59 per share a year ago. These ...
Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of ...
Sutro Biopharma, Inc. is part of the Zacks Medical - Biomedical and Genetics industry. Anika Therapeutics ANIK, another stock in the same industry, closed the last trading session 0.6% lower at ...
Sutro Biopharma Inc. BizSpotlight - Silicon Valley Business Journal
At Sutro Biopharma, we recognize the pressing need to tackle climate change head-on. Highlight and promote your company's achievements for $750.00. Submit Press Release ...
Is Sutro Biopharma, Inc. (STRO) A Good Stock To Buy?
Sutro Biopharma, Inc. (NASDAQ:STRO) is not the most popular stock in this group but hedge fund interest is still above average. Our overall hedge fund sentiment score for STRO is 71.8.
Sutro Biopharma Inc. BizSpotlight - Silicon Valley Business Journal
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients.
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $0.81 per share a year ago.
Similar Companies
Loading the latest forecasts...